Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
  2. Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations.

The FDA granted Rare Pediatric Disease designation to Monopar Therapeutics.

1 report, 1 independent Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The FDA granted Rare Pediatric Disease designation to Monopar Therapeutics.

Who's involved

What this event is mainly about
FDAMonopar Therapeutics

Keep exploring

Part of

Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations. All 2 developments

Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

The entities involved

Related events

Coverage

Newest first; wire copies grouped